OIG Advisory Opinion: 24-06

    Unfavorable

    Gene therapy manufacturer covering $70K fertility services for eligible patients

    Recorded opinion date:

    The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.

    What OIG Said

    OIG said this counts as remuneration, and raised flags on value, defensibility, and inducement risk.

    ⚠A gene therapy company proposed covering up to $70,000 in fertility-related services for patients prescribed its FDA-approved therapy, including Federal program patients whose insurance didn’t cover those services.

    ⚠OIG said this is remuneration: patients get valuable non-covered services, and hospitals may get therapy revenue from patients who otherwise wouldn’t proceed.

    ⚠OIG flagged the lack of valuation support, documentation, or commercial necessity evidence for the $70K benefit, and said this could improperly influence purchase and steerage decisions.

    ⚠Because payments weren’t tied to work, were high dollar, and lacked FMV support, OIG said no safe harbor applied and declined to offer protection.

    Diligence Checklist

    What you need to be ready to show in diligence

    ✓Prove any patient-facing benefit or support has clear scope, medical necessity, and a documented clinical rationale.

    ✓Have an independent FMV opinion for all support or access programs with economic value, including non-claim- based services.

    ✓Show support payments don’t correlate with product selection, therapy volume, or financial benefit to providers.

    ✓Document that support services are patient-directed, not routed through providers or commercial teams, and not used as marketing leverage.

    ✓Ensure any vendor-administered services don’t mask hidden steerage or backdoor referral incentives.

    If you’re doing this and you can’t prove commercial need, FMV support, and independence from referral volume, this is the profile OIG said will draw fire.

    Structure not diligence-ready?

    Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.

    Original PDF cover text

    UNFAVORABLE

    OIG WATCH 24-06

    Gene therapy manufacturer covering $70K fertility services for eligible patients

    Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.

    Source documents

    Preparing document preview…

    Ready to Move Forward?

    Let's explore how we can support your goals